Onward Medical
A leader in the spinal cord stimulation space, focused on targeted, programmed stimulation
Onward is the leader in the spinal cord stimulation space. They focus on targeted, programmed stimulation of the spinal cord to restore movement and other functions, alone or in combination with BCIs for thought-driven movement. Representing some of our most mature technologies, their first FDA approval is on track with the device going to market in 2024.
Technology
How they’re delivering breakthroughs
- 2 neuromodulation platforms via implantable (ARCIM) or external (ARCEX) technologies
- 10 FDA Breakthrough Device Designations, with almost 250 issued patents
Impact
How they’re making a difference
- Pivotal trial complete with positive top line results for ARCEX; positive interim outcomes also reported for ARCIM blood pressure indication
- First commercial sale expected in H1 2024
.jpeg)
